AI assistant
Armata Pharmaceuticals, Inc. — Earnings Release 2007
Aug 10, 2007
34152_rns_2007-08-10_466ba15a-7840-444a-9d07-953fb70323dd.zip
Earnings Release
Open in viewerOpens in your device viewer
8-K 1 v084108_8k.htm Unassociated Document Licensed to: vf Document Created using EDGARizer HTML 3.0.4.0 Copyright 2006 EDGARfilings, Ltd., an IEC company. All rights reserved EDGARfilings.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 7, 2007
| Targeted
Genetics Corporation |
| --- |
| (Exact
name of registrant as specified in its
charter) |
| Washington | 0-23930 | 91-1549568 |
|---|---|---|
| (State | ||
| or other jurisdiction of | ||
| incorporation) | (Commission | |
| File Number) | (IRS | |
| Employer Identification | ||
| No.) |
| 1100
Olive Way, Suite 100, Seattle, Washington | 98101 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |
Registrant's telephone number, including area code (206) 623-7612
| Not
Applicable |
| --- |
| (Former
name or former address if changed since last
report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425) |
| --- | --- |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On August 7, 2007, Targeted Genetics Corporation announced financial results for the second quarter ended June 30, 2007. A copy of the press release related to this announcement is attached as Exhibit 99.1 and is incorporated into this current report by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibits.
99.1 Press Release of Targeted Genetics Corporation dated August 7, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| /s/ David
J. Poston |
| --- |
| David
J. Poston |
| Vice
President Finance and Chief
Financial Officer |
INDEX TO EXHIBITS
| Exhibit
Number | Description |
| --- | --- |
| 99.1 | Press
Release of Targeted Genetics Corporation dated August 7,
2007 |